source
- Taiho and Cullinan report positive Phase 3 results for zipalertinib in EGFR exon 20 insertion lung cancerTaiho Oncology and Cullinan Therapeutics announced that their experimental drug zipalertinib achieved positive results in a Phase 3 trial for first‑line treatment of lung cancer patients whose tumo…
- PDS Biotechnology pauses phase 3 head-and-neck trial to prioritize colorectal cancer immunotherapyPDS Biotechnology announced it is stopping work on its phase 3 head and neck cancer therapy, Versamune HPV (PDS0101), in order to reallocate resources to a different drug program. The halted trial…